---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-023381"
form_type: "8-K/A"
ticker: "PMI"
cik: "0002030617"
company_name: "Picard Medical, Inc."
filed_at: "2026-07-13T11:57:57+00:00"
generated_at: "2026-07-13T12:00:06.228374+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Picard Medical Q1 revenue up 85% YoY; gross margin improves to 24%

## Summary
- Revenue for first three months of 2026 increased 85% YoY; U.S. revenue up 116%.
- Gross margin improved to 24% from -4% in 2025.
- Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.
- Interim CEO Richard Fang acknowledges recent leadership changes but reaffirms mission.
- Annual meeting set for July 17, 2026; proposals include director elections and capital structure amendments.

## SEC filing metadata
- accession: 0001437749-26-023381
- form_type: 8-K/A
- ticker: PMI
- cik: 0002030617
- company_name: Picard Medical, Inc.
- filed_at: 2026-07-13T11:57:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030617/000143774926023381/0001437749-26-023381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030617/000143774926023381/pmi20260710_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-023381
- JSON: https://secwatch.observer/filing/0001437749-26-023381.json
- Plain text: https://secwatch.observer/filing/0001437749-26-023381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.